Nevada Chapter of AACE Cardio Metabolic Conference

Las Vegas, NV US
November 18, 2017

Welcome, and thank you for attending the Nevada Chapter of the American Association of Clinical Endocrinologists Cardio Metabolic Conference.

The Nevada Chapter of AACE program committee has worked very hard to provide a relevant activity for the practicing clinical physician and other healthcare providers seeking education with an emphasis in endocrine disease.

This program has been planned to provide pertinent scientific and clinical information to help you achieve the best solutions in the diagnosis and therapeutic management of patients presenting with endocrine disease. Attendees will obtain updates in not only common and uncommon endocrine disorders, but also newer treatment modalities.

Providing exceptional patient care requires continuing high quality education. The American Association of Clinical Endocrinologists (AACE) was founded in 1991 by a visionary group of leaders to serve as the active voice for clinical endocrinologists. The impetus behind AACE's efforts has always been quality and cost-effective patient care for those with endocrine diseases and disorders. We hope that you will find this program of great value to you in your practice.

Target Audience

Endocrinologists, primary care practitioners, advance practice clinicians, cardiologists, nephrologists, dietitians, CDEs and pharmacists in Las Vegas, NV.

Learning Objectives

  1. Describe the association between insulin resistance and physiological derangements
  2. Define insulin resistance as it relates to the Adult Treatment Panel III
  3. Describe methods to make the diagnosis of Insulin Resistance Syndrome
  4. Discuss the pros and cons of each drug class currently available to treat dysglycemia
  5. Know how to apply the AACE Comprehensive Diabetes Management Algorithm into daily clinical care
  6. Review the breakthrough cardiovascular outcome studies with glucose lowering drugs
  7. Discuss the recent studies on treating hypertension.
  8. Review the AACE hypertension guidelines. Does the evidence support the guidelines?
  9. What should the blood pressure goal be for people with type 2 DM?
  10. Discuss the recent studies on treating dyslipidemia including PCSK9 inhibitors and Anaceptrapib
  11. Review the AACE and ACC/AHA dyslipidemia guidelines. Does the evidence support the guidelines?
  12. Discuss the rationale why the dyslipidemia guidelines focus on LDL-C vs. other lipid parameters like non-HDL-C, TC/HDL-C ratio, and Apo B.
  13. Recognize that cardiovascular disease continues to be the number one cause of death especially in people with diabetes
  14. Discuss key genes and inflammatory biomarkers testing involved in the development of cardiovascular disease and atherosclerosis
  15. Identify non-invasive testing that help to identify a person's risk for cardiovascular disease and atherosclerosis
  16. Discuss the creation of a new paradigm shift that focuses on the disease itself (atherosclerosis) rather than relying solely on risk factor modification.
Additional information
Available for MOC Points?: 
No
Practice Area: 
Diabetes
Hypoglycemia
Obesity
General Endo
Course summary
Available credit: 
  • 4.25 AMA
  • 4.25 Attendance
Course opens: 
11/18/2017
Course expires: 
11/18/2018
Event starts: 
11/18/2017 - 7:00am
Event ends: 
11/18/2017 - 12:50pm
Cost:
$0.00
Rating: 
0

Program Agenda

* Please click the program's title to view each presentation.

Saturday, November 18, 2017

7:00 – 7:50 AMRegistration & Continental Breakfast
7:50 – 8:00 AMWelcome, Introductions and Program Overview
8:00 – 8:45 AMInsulin Resistance – The Gateway to Several Physiological Derangements Which Ultimately Impact on the Arterial Wall 
M. Fariba Rahnema, MD, CDE, ECNU 
Objectives:
  1. Describe the association between insulin resistance and physiological derangements
  2. Define insulin resistance as it relates to the Adult Treatment Panel III
  3. Describe methods to make the diagnosis of Insulin Resistance Syndrome
8:45 – 9:30 AMPharmacology Update: 14 Diabetes Classes and Counting! 
Quang Nguyen, DO, FACP, FACE, FTOS 
Objectives:
  1. Discuss the pros and cons of each drug class currently available to treat dysglycemia
  2. Know how to apply the AACE Comprehensive Diabetes Management Algorithm into daily clinical care
  3. Review the breakthrough cardiovascular outcome studies with glucose lowering drugs
9:30 – 10:00 AMHypertension-How Low Do We Go?
Kenneth Izuora, MD, MBA, FACE 
Objectives:
  1. Discuss the recent studies on treating hypertension.
  2. Review the AACE hypertension guidelines. Does the evidence support the guidelines?
  3. What should the blood pressure goal be for people with type 2 DM?
10:00 – 10:30 AMBreak
10:30 – 11:00 AMDyslipidemia-Is Lower LDL-C Really Better? 
Omar Wani, MD, FACC, FASE, FSCAI 
Objectives:
  1. Discuss the recent studies on treating dyslipidemia including PCSK9 inhibitors and Anaceptrapib
  2. Review the AACE and ACC/AHA dyslipidemia guidelines. Does the evidence support the guidelines?
  3. Discuss the rationale why the dyslipidemia guidelines focus on LDL-C vs. other lipid parameters like non-HDL-C, TC/HDL-C ratio, and Apo B.
11:00 – 12:15 PMCardiovascular Disease, Diabetes, and Atherosclerosis-Know Your Risk: Is it Time for a Paradigm Shift? 
Claude K. Lardinois, MD, FACP, MACN, FACE 
Objectives:
  1. Recognize that cardiovascular disease continues to be the number one cause of death especially in people with diabetes
  2. Discuss key genes and inflammatory biomarkers testing involved in the development of cardiovascular disease and atherosclerosis
  3. Identify non-invasive testing that help to identify a person's risk for cardiovascular disease and atherosclerosis
  4. Discuss the creation of a new paradigm shift that focuses on the disease itself (atherosclerosis) rather than relying solely on risk factor modification.
12:15 – 12:45 PMPanel Discussion with the Faculty 
Claude K. Lardinois, MD, FACP, MACN, FACE
M. Fariba Rahnema, MD, CDE, ECNU
Kenneth Izuora, MD, MBA, FACE
Quang Nguyen, DO, FACP, FACE, FTOS
Omar Wani, MD, FACC, FASE, FSCAI
12:45 – 12:50 PMClosing Remarks and Conference Wrap‐Up 
Las Vegas Springs Preserve
333 S. Valley View Blvd.
Las Vegas, NV 89107
United States

*Kenneth Izuora, MD, MBA, FACE
President, Nevada Chapter of AACE
Associate Professor of Medicine
University of Nevada Las Vegas School of Medicine
Las Vegas, NV

*Claude K. Lardinois, MD, FACP, MACN, FACE
Emeritus Professor of Medicine
University of Nevada School of Medicine
Reno, NV
Board Certified Endocrinology Consultant
Medical Director, American Health Care
Rocklin, CA

Quang Nguyen, DO, FACP, FACE, FTOS
Medical Director, Las Vegas Endocrinology
Clinical Associate Professor, AZCOM
Adjunct Associate Professor, TUNCOM
Henderson, NV

*M. Fariba Rahnema, MD, CDE, ECNU
Valley Endocrinology
Las Vegas, NV

Omar Wani, MD, FACC, FASE, FSCAI
Interventional Cardiologist
Mountain Heart, LLC
Flagstaff, AZ

* Indicates a member of the Program Committee and Faculty.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association of Clinical Endocrinologists (AACE) and the Nevada Chapter of AACE. The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 4.25 AMA
  • 4.25 Attendance

Accreditation Period

Course opens: 
11/18/2017
Course expires: 
11/18/2018

Price

Cost:
$0.00
Please login or register to take this course.